Publicaciones (74) Publicaciones de María Luisa Martín Calvo

2024

  1. Chronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes

    Biomedicine and Pharmacotherapy, Vol. 176

2023

  1. Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands

    International Journal of Epidemiology, Vol. 52, Núm. 4, pp. E241-E252

  2. Fármacos que actúan modulando la actividad enzimática

    Fundamentos de farmacología básica y clínica (Editorial Médica Panamericana), pp. 101-112

  3. Renal Sympathetic Hyperactivity in Diabetes Is Modulated by 5-HT1D Receptor Activation via NO Pathway

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

2022

  1. Effect of sarpogrelate treatment on 5-HT modulation of vascular sympathetic innervation and platelet activity in diabetic rats

    Biomedicine and Pharmacotherapy, Vol. 153

  2. Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  3. Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes

    Life Sciences, Vol. 293

2021

  1. Trends in the use of anxiolytics in castile and leon, spain, between 2015–2020: Evaluating the impact of covid-19

    International Journal of Environmental Research and Public Health, Vol. 18, Núm. 11

  2. Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment

    Journal of Pharmacological Sciences, Vol. 147, Núm. 1, pp. 48-57

2020

  1. Dopamine D4 receptor subtype activation reduces the rat cardiac parasympathetic discharge

    Pflugers Archiv European Journal of Physiology, Vol. 472, Núm. 12, pp. 1693-1703

2019

  1. Fluoxetine oral treatment discloses 5-HT 1D receptor as vagoinhibitor of the cardiac cholinergic neurotransmission in rat

    Canadian Journal of Physiology and Pharmacology, Vol. 97, Núm. 2, pp. 90-98

  2. Hypertension exhibits 5-HT 4 receptor as a modulator of sympathetic neurotransmission in the rat mesenteric vasculature

    Hypertension Research, Vol. 42, Núm. 5, pp. 618-627

2017

  1. 5-HT modulates the rat mesenteric vasopressor outflow by 5-HT1D sympatholytic receptors

    Clinical and Experimental Pharmacology and Physiology, Vol. 44, Núm. 12, pp. 1224-1231

  2. Chronic Sarpogrelate Treatment Reveals 5-HT7 Receptor in the Serotonergic Inhibition of the Rat Vagal Bradycardia

    Journal of Cardiovascular Pharmacology, Vol. 69, Núm. 1, pp. 13-22

2016

  1. 5-HT2 receptor blockade exhibits 5-HT vasodilator effects via nitric oxide, prostacyclin and ATP-sensitive potassium channels in rat renal vasculature

    Vascular Pharmacology, Vol. 79, pp. 51-59

  2. Posibilidades de los fármacos en situaciones patológicas relacionadas con la serotonina

    Farmajournal, Vol. 1, Núm. 2, pp. 177-178

2015

  1. 5-HT1D receptor inhibits renal sympathetic neurotransmission by nitric oxide pathway in anesthetized rats

    Vascular Pharmacology, Vol. 72, pp. 172-180

  2. Pharmacological evidence that 5-HT1D activation induces renal vasodilation by NO pathway in rats

    Clinical and Experimental Pharmacology and Physiology, Vol. 42, Núm. 6, pp. 640-647

2014

  1. The role of endothelium-derived hyperpolarizing factor and cyclooxygenase pathways in the inhibitory serotonergic response to the pressor effect elicited by sympathetic stimulation in chronic sarpogrelate treated rats

    European Journal of Pharmacology, Vol. 731, Núm. 1, pp. 80-87

2013

  1. Peripheral 5-HT1D and 5-HT7 serotonergic receptors modulate sympathetic neurotransmission in chronic sarpogrelate treated rats

    European Journal of Pharmacology, Vol. 714, Núm. 1-3, pp. 65-73